Drug Trial Radar · NCT06083753
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Nov 6, 2023
Primary completion
Jul 14, 2025
Study completion Aug 4, 2025
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
Conditions
- Relapsing Remitting Multiple Sclerosis
Interventions
PIPE-307 Dose ADrug
Subjects will receive daily oral doses of PIPE-307
PIPE-307 Dose BDrug
Subjects will receive daily oral doses of PIPE-307
PlaceboDrug
Subjects will receive daily oral matching dose of Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAE)Time frame: From baseline to week 26 (end of treatment period)
- Change in binocular 2.5% low contrast letter acuity (LCLA)Time frame: From baseline to week 26 (end-of-study)
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Xenosciences
Phoenix, Arizona
Arizona Neuroscience Research, LLC
Phoenix, Arizona
Alta Bates Summit Medical Center
Berkeley, California
Colorado Springs Neurological Associates
Colorado Springs, Colorado
MS and Neuromuscular Center of Excellence
Clearwater, Florida
Aqualane Clinical Research
Naples, Florida
Shepherd Center
Atlanta, Georgia
University of Kansas Medical Center
Kansas City, Kansas
Neurology Center of New England P.C.
Foxborough, Massachusetts
Washington University School of Medicine
St Louis, Missouri
University of New Mexico/Health Science Center/MIND Imaging Center/MS Specialty Clinic
Albuquerque, New Mexico
Dent Neurologic Institute
Amherst, New York
Neurological Associates of Long Island, P.C.
Lake Success, New York
Oklahoma Research Foundation - MS Center of Excellence
Oklahoma City, Oklahoma
Sibyl Wray Neurology PC
Knoxville, Tennessee
University of Texas Health Science Center at Houston
Houston, Texas
Clinical Trial Network
Houston, Texas
Bhupesh Dihenia, MD, PA
Lubbock, Texas
Virginia Mason Medical Center
Seattle, Washington
UW Medicine MS Center
Seattle, Washington
Multicare Neuroscience Center of Washington
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.